vs
Side-by-side financial comparison of Four Corners Property Trust, Inc. (FCPT) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $78.2M, roughly 1.1× Four Corners Property Trust, Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 9.4%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 8.4%).
Four Corners Property Trust, Inc. is a publicly traded real estate investment trust that acquires, owns, and manages a portfolio of high-quality net-leased commercial properties. Its assets are primarily restaurant and retail locations across the United States, with tenants largely operating in stable consumer-facing industry segments with proven operational performance.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FCPT vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $78.2M | $86.8M |
| Net Profit | $30.4M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 55.3% | -84.7% |
| Net Margin | 38.8% | — |
| Revenue YoY | 9.4% | 17.7% |
| Net Profit YoY | 16.0% | — |
| EPS (diluted) | $0.28 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $78.2M | — | ||
| Q4 25 | $75.7M | $86.8M | ||
| Q3 25 | $74.1M | $67.5M | ||
| Q2 25 | $72.8M | $60.0M | ||
| Q1 25 | $71.5M | $49.3M | ||
| Q4 24 | $68.3M | $73.7M | ||
| Q3 24 | $66.8M | $58.6M | ||
| Q2 24 | $66.5M | $31.1M |
| Q1 26 | $30.4M | — | ||
| Q4 25 | $29.4M | — | ||
| Q3 25 | $28.8M | $-91.3M | ||
| Q2 25 | $27.9M | $-111.7M | ||
| Q1 25 | $26.2M | $-116.2M | ||
| Q4 24 | $26.2M | — | ||
| Q3 24 | $25.6M | $-83.5M | ||
| Q2 24 | $24.7M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | 55.3% | — | ||
| Q4 25 | — | -84.7% | ||
| Q3 25 | — | -140.7% | ||
| Q2 25 | — | -189.8% | ||
| Q1 25 | — | -245.8% | ||
| Q4 24 | — | -117.5% | ||
| Q3 24 | — | -152.1% | ||
| Q2 24 | — | -327.6% |
| Q1 26 | 38.8% | — | ||
| Q4 25 | 38.9% | — | ||
| Q3 25 | 38.9% | -135.3% | ||
| Q2 25 | 38.3% | -186.2% | ||
| Q1 25 | 36.6% | -235.5% | ||
| Q4 24 | 38.3% | — | ||
| Q3 24 | 38.3% | -142.7% | ||
| Q2 24 | 37.1% | -312.2% |
| Q1 26 | $0.28 | — | ||
| Q4 25 | $0.27 | — | ||
| Q3 25 | $0.28 | — | ||
| Q2 25 | $0.28 | $-0.33 | ||
| Q1 25 | $0.26 | $-0.36 | ||
| Q4 24 | $0.27 | $-0.24 | ||
| Q3 24 | $0.27 | $-0.28 | ||
| Q2 24 | $0.27 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.6M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.7B | $698.6M |
| Total Assets | $3.0B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $29.6M | — | ||
| Q4 25 | $12.1M | $297.0M | ||
| Q3 25 | $6.7M | $300.8M | ||
| Q2 25 | $6.0M | $301.2M | ||
| Q1 25 | $22.3M | $359.7M | ||
| Q4 24 | $4.1M | $323.8M | ||
| Q3 24 | $44.5M | $397.5M | ||
| Q2 24 | $17.2M | $412.5M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.2B | — |
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.6B | $698.6M | ||
| Q3 25 | $1.5B | $702.3M | ||
| Q2 25 | $1.5B | $698.5M | ||
| Q1 25 | $1.4B | $767.9M | ||
| Q4 24 | $1.5B | $710.4M | ||
| Q3 24 | $1.4B | $773.5M | ||
| Q2 24 | $1.3B | $768.5M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $2.9B | $913.2M | ||
| Q3 25 | $2.8B | $904.9M | ||
| Q2 25 | $2.8B | $907.4M | ||
| Q1 25 | $2.7B | $966.7M | ||
| Q4 24 | $2.7B | $910.4M | ||
| Q3 24 | $2.6B | $991.1M | ||
| Q2 24 | $2.5B | $964.3M |
| Q1 26 | — | — | ||
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.84× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.92× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $192.3M | $-52.6M | ||
| Q3 25 | $48.9M | $-78.7M | ||
| Q2 25 | $43.8M | $-67.4M | ||
| Q1 25 | $51.6M | $-103.7M | ||
| Q4 24 | $144.1M | $-73.3M | ||
| Q3 24 | $43.4M | $-59.0M | ||
| Q2 24 | $39.7M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 6.53× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.57× | — | ||
| Q1 25 | 1.97× | — | ||
| Q4 24 | 5.51× | — | ||
| Q3 24 | 1.70× | — | ||
| Q2 24 | 1.61× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FCPT
| Rental revenue | $69.8M | 89% |
| Restaurant revenue | $8.4M | 11% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
